We have made the difficult decision to evaluate strategic alternatives and discontinue our allogeneic CAR-T cell therapy programs due to challenges securing necessary capital to responsibly advance these programs. Read more: bit.ly/47506ys $CRBU

We’re a finalist for @Citeline’s 2026 Best Oncology R&D Advance Award! This recognition serves as a testament to the potential of vispa-cel, our pivotal-ready allogeneic CAR-T cell therapy, to expand access for patients. See all the finalists: bit.ly/4hitrLL $CRBU

Missed our CB-011 data presentation at EHA this year? Come join us in Scotland next week at the 23rd @Myeloma_Society Annual Meeting for an encore poster presentation. #IMS26 #CRISPR #CellTherapy $CRBU

In Boston next week? Check out the presentations from our very own Enrique Zudaire and Justin Skoble at the 11th Annual CAR-TCR Summit. Learn more: bit.ly/4chYdS6 #CRISPR #CellTherapy $CRBU

Today we reported our Q2 earnings. Learn more in our second quarter 2026 financial results and business update: bit.ly/4qj20V1 #CRISPR #CellTherapy $CRBU

For patients facing relapsed or refractory #lymphoma, timely access to treatment can be critical. Watch Dr. Mehdi Hamadani share his perspective on treatment decisions and the value of an off-the-shelf option. Watch the full video here: bit.ly/44JKhw0 #CellTherapy

#ICYMI @MM_Hub published an interview with Dr. Binod Dhakal about the CB-011 data at #EHA2026. Watch below to hear about the potential for this single-dose, off-the-shelf approach to help broaden CAR-T cell treatment access. #CellTherapy #CRISPR $CRBU

Our ANTLER abstract was accepted as an e-poster for PPLC 2026, featuring previously presented data for vispa-cel. You can view our poster via the conference app’s ePoster Gallery or access it on Caribou’s website: bit.ly/4hnaw2v #CellTherapy #CRISPR $CRBU

#ICYMI @lymphomahub’s interview with Dr. Stephen Schuster is live, discussing the vispa-cel data presented at #EHA2026 that demonstrate durable, auto-CAR-T-like responses from a single, off-the-shelf dose. Listen below. #CellTherapy #CRISPR $CRBU

Join us tomorrow as Ben Schilling, senior manager of process development, discusses how to leverage data and automation strategies to optimize process development for Caribou’s allogeneic cell therapies. Learn more: bit.ly/3R70tEk #CellTherapy #CRISPR $CRBU

#ICYMI Dr. Binod Dhakal spoke with @MyelomaEurope about the CB-011 data presented at #EHA2026 and what it means for patients. Check out the full interview below. #CellTherapy #CRISPR $CRBU

We’re participating in the @HCWCO 4th Annual Cell Therapy Virtual Conference. Tune in tomorrow for the fireside chat with our president and CEO, Rachel Haurwitz, PhD. Learn more: bit.ly/3SvzHG0 Listen to the webcast: bit.ly/4g7LwvK #CellTherapy #CRISPR $CRBU

The excitement at #BIO2026 continues! Join Rachel Haurwitz, PhD, President & CEO, and a panel of experts as they dive into what the next decade of biotech looks like to help support patients. Learn more about the session: bit.ly/4eBR0MJ

Interested to learn more about the future of CAR-T cell therapy in the community? Don’t miss the #BIO2026 session tomorrow featuring our very own president and CEO, Rachel Haurwitz, PhD. Join us: bit.ly/4vOoH4Y #CellTherapy #CRISPR $CRBU

We’re looking forward to attending the @BIOConvention next week! Our president and CEO, Rachel Haurwitz, PhD, will be speaking about expanding access to CAR-T cell therapies. Read more: bit.ly/4vOoH4Y #CellTherapy #CRISPR $CRBU #BIO2026

On this final day of #EHA2026, Dr. Binod Dhakal will be presenting longer follow-up data on CB-011 from the dose escalation portion of our CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma. Don’t miss it! #CellTherapy #CRISPR $CRBU

At #EHA2026, we are reminded of the impact that patients, like Beth, have in advancing research and potential treatment options by participating in clinical trials. Today, we are honored to share her story. Watch the full video: bit.ly/4ggNWYX #Lymphoma #CellTherapy

Always great to catch up with @bradloncar and @BiotechTV. Watch the interview to get an overview of the exciting data being  presented on our allogeneic CAR-T cell programs for #lymphoma and #multiplemyloma at #EHA2026.

If you’re in Stockholm for #EHA2026, check out Dr. Stephen Schuster’s presentation of our vispa-cel data to hear about long-term durability after a single dose of vispa-cel in patients with relapsed or refractory B cell non-Hodgkin lymphoma. #CellTherapy #CRISPR $CRBU

We’re pleased to share longer follow-up dose escalation data for CB-011 in patients with relapsed or refractory multiple myeloma. Learn more during an oral presentation at #EHA2026 and here: bit.ly/4vmQz0h #CellTherapy #CRISPR $CRBU